Deadline: 15-May-2025
Applications are now open for the Gilead Australia Fellowship Grants Program to support innovative local research initiatives to improve patient outcomes.
Aims
- The Fellowship aims to support:
- projects with a clinical and ‘real-world’ focus
- the development and implementation of best practice to enhance patient outcomes
- research in the specific disease areas of HIV, chronic viral hepatitis and/ or haematological malignancies.
Focus Areas
- HIV
- The Gilead Australia Fellowship Program supports innovative projects to help improve the lives of people living with or at risk of acquiring HIV. The 2026 program is looking to support initiatives across health care organisations that support the ambition to ending the epidemic, everywhere for everyone. In particular, projects that aim to address the following are welcomed:
- Improving interest and uptake of screening and linkage to care to identify undiagnosed people living with HIV in high prevalence and/or underserved populations.
- Identifying the reasons people living with HIV change therapies, disengage from treatment, and/or are lost to follow-up, and strategies to address these.
- Understanding the impact of HIV treatments on quality of life for people with HIV, including people in older age groups, culturally and linguistically diverse people, women and trans and gender diverse people.
- Identifying reasons why certain at risk/priority populations who may benefit from HIV prevention strategies are not currently engaging in them, including people living in middle and outer suburbs of capital cities, regional and/or remote areas, culturally and linguistically diverse people, overseas born migrants, people in younger age groups.
- Identifying implementation strategies to improve PrEP awareness, uptake, and ongoing access/linkage of people who may benefit from PrEP for HIV prevention.
- The Gilead Australia Fellowship Program supports innovative projects to help improve the lives of people living with or at risk of acquiring HIV. The 2026 program is looking to support initiatives across health care organisations that support the ambition to ending the epidemic, everywhere for everyone. In particular, projects that aim to address the following are welcomed:
- Viral Hepatitis
- The Gilead Australia Fellowship Program is looking to support projects and initiatives which ultimately lead to an improvement in patient care within the field of viral hepatitis and primary biliary cholangitis (PBC). Priority will be given to those projects that focus on the optimisation of the pathways for the diagnosis and management of hepatitis C virus (HCV), hepatitis delta virus (HDV) and PBC. In particular, projects that aim to address the following are welcomed:
- Improving the care and outcomes of people living with HCV.
- Developing strategies to reduce HCV re-infections, lost-to-follow-up and long-term complications.
- Describing the impact of alternative delivery models of care for people living with chronic viral hepatitis.
- Describing the impact of moderate to severe pruritus on the quality of life of PBC patients.
- The Gilead Australia Fellowship Program is looking to support projects and initiatives which ultimately lead to an improvement in patient care within the field of viral hepatitis and primary biliary cholangitis (PBC). Priority will be given to those projects that focus on the optimisation of the pathways for the diagnosis and management of hepatitis C virus (HCV), hepatitis delta virus (HDV) and PBC. In particular, projects that aim to address the following are welcomed:
- CAR T-Cell Therapy
- The Gilead Australia Fellowship Program supports innovative research and best practice sharing to help improve the lives of patients within the field of CAR T cell therapy and haemato-oncology. The Fellowship Program seeks to support projects and initiatives that lead to improvements in patient care where CAR T cell therapies are currently used (i.e relapsed or refractory LBCL, MCL, adult ALL or FL). This includes, but is not limited to, activities such as:
- Initiatives to enhance remote access to care, such as telehealth services, remote monitoring, or virtual shared care pathways between referring and CAR T treatment centres.
- Development of programs or tools focused on understanding and addressing carers’ perspectives, including educational resources, support frameworks, or tools to assess the impact of caregiving on quality of life.
- New initiatives to improve the efficiency and coordination of patient care and shared care pathways between referring and CAR T treatment centres.
- Real-world evidence studies or outcomes research assessing the long-term impact of CAR T therapies on patient populations, including treatment patterns, safety, efficacy, or quality of life outcomes.
- The Gilead Australia Fellowship Program supports innovative research and best practice sharing to help improve the lives of patients within the field of CAR T cell therapy and haemato-oncology. The Fellowship Program seeks to support projects and initiatives that lead to improvements in patient care where CAR T cell therapies are currently used (i.e relapsed or refractory LBCL, MCL, adult ALL or FL). This includes, but is not limited to, activities such as:
What is the focus of projects included in the fellowship?
- Successful applications will focus on investigating solutions to improve outcomes for people living with, at risk of acquiring, HIV, chronic viral hepatitis, primary biliary cholangitis (PBC), and/ or haematological malignancies
- Projects may be based on sociological and epidemiological aspects of patient care, as well as practical aspects. Applications for community-based projects that may not necessarily fall under traditional grant criteria are welcomed.
- Please note that basic science research and clinical research based on specific therapeutic agents are out of scope for the Gilead Australia Fellowship Grants Program.
Funding Information
- The total funding available for the 2026 Grants Program is $300,000 AUD.
- The requested level of funding should be stated at the time of application.
- Funding is contingent on the project:
- being granted ethics approval (if required)
- concluding in no more than 18 months after execution of agreement
- The maximum award for successful proposals will be $60,000 AUD.
- Amounts awarded may vary, with the exact amount of funding allocated to each project dependent on the nature of the project. Funding is entirely independent of the use of any therapeutic agent.
Funding Support for Local Australian Research
- Researchers in Australia currently face increasing competition for limited funding, particularly for projects with a local or community focus. In recognition of these projects and their benefits to patient care, the Fellowship aims to help bridge the gap in local Australian research funding.
- The Fellowship has been running successfully in Australia for over a decade, providing funding to novel projects across Australia that can inform and shape best practice in patient care. Founded in 2012, the Fellowship has since awarded over $3,500,000, to Australian led research and community projects.
Judging Criteria
- The applications will be reviewed by a judging panel made up of experts from across Australia recognised for their contributions to research. Project applications within the specified themes will be judged against the following criteria:
- Innovative projects aimed at improving patient care and/or guiding healthcare policy
- Clear demonstration of need and relevance to local clinical practice
- Clarity and specificity of key steps involved
- Measurable objectives and outcomes
- Collection/reporting of actual project-related cost
- Collection/reporting of patient-related outcomes
- Demonstration of clear evaluation plans
- Clear project timelines
- Clear demonstration of ability to meet the required timelines
- Clarity in the budget
- High likelihood of appropriate ethics approval in the estimated time frame
For more information, visit Gilead.
